Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: Indirect, exploratory comparisons

International Journal of General Medicine

Volumn 5, Issue , 2012, Pages 391-398

  Ascher Svanum, Haya ^a   Montgomery, William S ^b   McDonnell, David P ^a   Coleman, Kristina A ^c   Feldman, Peter D ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c OPTUM   (United States)

Author keywords

Antipsychotic drugs; Intramuscular injection; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

LONG ACTING DRUG; OLANZAPINE; PLACEBO; RISPERIDONE;

ADULT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL STUDY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT COMPLETION RATE; TREATMENT OUTCOME;

EID: 84877103821     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S29052     Document Type: Review

References (56)

1. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47-53.
2. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67(10):1542-1550.
3. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64 Suppl 16:34-40.
4. Marder SR. Overview of partial compliance. J Clin Psychiatry. 2003; 64 Suppl 16:3-9.
5. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67 Suppl 5:15-18.
6. Rainer MK. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat. 2008;4(5): 919-927.
7. Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother. 2011;12(4):627-633.
8. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebocontrolled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30(3):235-244.
9. Nahata T, Saini TR. Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design. PDA J Pharm Sci Technol. 2009;63(2):113-122.
10. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
12. Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence. 2008;2:67-77.
13. Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics. An integrated analysis. J Clin Psychopharmacol. 2007;27(3): 252-258.
14. Bitter I, Treuer T, Dyachkova Y, Martenyi F, McBride M, Ungvari GS. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Neuropsychopharmacol. 2008;18(3): 170-180.
15. Cooper D, Moisan J, Gaudet M, Abdous B, Gregoire JP. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can J Psychiatry. 2005;50(14):901-908.
16. Dossenbach M, Erol A, el Mahfoud Kessaci M, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004;65(3):312-321.
17. Gibson PJ, Damler R, Jackson A, Wilder T, Ramsey JL. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health. 2004;7(1):22-35.
18. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235-244.
19. Jayaram MB, Hosalli PM, Stroup TS. Risperidone versus olanzapine for treatment of schizophrenia. Schizophr Bull. 2007;33(6): 1274-1276.
20. Mudge MAC, Davey PJ, Coleman KA, et al. A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a metaanalysis of randomised clinical trials. Int J Psychiatry Clin Pract. 2005;9(1):3-15.
21. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006;9(2):77-89.
22. Williams R, Kopala L, Malla A, Smith G, Love L, Balshaw R. Medication decisions and clinical outcomes in the Canadian National Outcomes Measurement Study in Schizophrenia. Acta Psychiatr Scand Suppl. 2006;113(430):12-21.
23. Eli Lilly and Company. Abbreviated clinical study report: an openlabel study of intramuscular olanzapine depot in patients with schizophrenia or schizoaffective disorder. 2007. Registered at: http://www. ClinicalTrials.gov, July 26, 2004, as NCT00088465 (study code: F1D-MC-HGKB).
24. Ascher-Svanum H, Peng X, Montgomery W, et al. Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia. Eur Psychiatry. 2011;26(5):313-319.
25. McDonnell DP, Andersen SW, Detke HC, Zhao F, Watson SB. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights Psychiatry. 2011;2011(3):37-47.
26. Chue P, Llorca PM, Duchesne I, Leal A, Rosillon D, Mehnert A. Hospitalization rates in patients during long-term treatment with longacting risperidone injection. J Appl Res. 2005;5(2):266-274.
27. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-1257.
28. Gharabawi GM, Gearhart NC, Lasser RA, et al. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry. 2007;6:3.
29. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone-analysis of long-term efficacy. J Psychopharmacol. 2005;19(Suppl 5):15-21.
30. Lee MS, Ko YH, Lee SH, et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol. 2006;21(6):399-407.
31. Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2007;17(2):138-144.
32. Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287-296.
33. Rossi A, Bagala A, Del Curatolo V, et al. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol. 2009;24(7):574-583.
34. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year doubleblind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2006;67(8):1194-1203.
35. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790-799.
36. Eli Lilly and Company. Clinical study report: a double-blind, randomised study comparing intramuscular olanzapine depot to oral olanzapine and low-dose intramuscular olanzapine depot in the maintenance therapy of patients with schizophrenia. 2007. Registered at: http://www.ClinicalTrials.gov, July 26, 2004, as NCT00088491 (study code: F1D-MC-HGKA).
37. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181-189.
38. Eli Lilly and Company. Clinical pharmacology study report: pharmacokinetic characterization of intramuscular olanzapine depot as a function of particle size distribution. 2005. Registered at: http://www.ClinicalTrials. gov, October 21, 2004, as NCT00094640 (study code: F1D-EW-LOBS).
39. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6): 1125-1132.
40. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and eff icacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004;65(8):1084-1089.
41. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
42. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238.
43. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Publication ADM 76-338. Bethesda, MD: United States Department of Health, Education, and Welfare; 1976.
44. Gaebel W, Riesbeck M, von Wilmsdorff M, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20(5):310-316.
45. Gianfrancesco FD, Rajagopalan K, Sjatovic M, Wang RH. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res. 2006;144(2-3):177-189.
46. Haro JM, Novick D, Suarez D, Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009;43(3): 265-273.
47. Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009; 113(1):49-55.
48. Hodgson R, Belgamwar R, al-Tawarah Y, MacKenzie G. The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire. Hum Psychopharmacol. 2005;20(2):141-147.
49. Kreyenbuhl J, Slade EP, Medoff DR, et al. Time to discontinuation of first-and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res. 2011;131(1-3):127-132.
50. Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J. 2006;333(7561):224.
51. Detke HC, Weiden PJ, Llorca PM, et al. Open label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. [Abstract]. Schizophr Bull. 2011;37 Suppl 1:300.
52. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011; 364(9):842-851.
53. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111-117.
54. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12):2378-2386.
55. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry. 2007;19:131-139.
56. Lambert T, Olivares JM, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry. 2011;10:10.